Our Expert Network

1. Comparing Advanced Modality Needs, Part 1: Manufacturing 11/13/2026

   ADCs, AOCs, ATMPs, cell and gene therapies, and oligonucleotide therapeutics represent distinct but interconnected approaches to precision medicine. Let's take a closer look at their manufacturing needs.

2. 4 Delivery Science Lessons For RNA Developers 11/11/2026

   Drawing on published science, current guidance, and the author's own perspective, four delivery science lessons become clear for RNA developers.

3. Two Parallel Trials, A Potential New Option For Protection From COVID-19 11/10/2026

   Invivyd’s Michael Mina, MD, Ph.D., discusses LIBERTY and DECLARATION, exploring how monoclonal antibodies could expand COVID-19 protection alongside vaccines.

4. Advancing circRNA Therapeutics: Tackling Development And Manufacturing Challenges 11/9/2026

   Wiklund discusses the advantages of circRNA, Circio’s unique approach and the manufacturing and delivery challenges facing the field, and where advancement opportunities exist.

5. Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions 10/30/2026

   This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.

6. Antibody–Oligonucleotide Conjugates, Part 3: Analytical Control 10/23/2026

   Let's delve into analytical control strategy, OAR/DAR measurement, bioanalytical characterization, stability and formulation, and more.

7. Antibody–Oligonucleotide Conjugates, Part 2: Manufacturing 10/16/2026

   Let's delve into manufacturing strategy, conjugation chemistry, process development and scale-up, and purification: the central manufacturing challenge.

8. CDMOs Co-Author The RNA Ecosystem 10/14/2026

   Praise to the RNA innovators, and our innovative service providers. You’ve brought us a long way. Still, that progress hasn’t necessarily made it easier to strategize the outsourcing of specific RNA-based projects. We’ve expanded development programs therapeutically and dialed up nuanced production requirements. So the current question is what will the RNA outsourcing ecosystem look like a few years from now? Here’s some expert analysis.

9. Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan 10/9/2026

   The emergence of antibody–oligonucleotide conjugates (AOCs) addresses delivery issues with huge potential. Let's look at how to approach your development plan with molecular architecture, defining the target product profile, and CQAs.

10. Can Engineering The Passenger Strand Improve siRNA Performance? 10/8/2026

    How can we make the passenger strand easier to reject while keeping the siRNA duplex sufficiently stable before it reaches the machinery that activates it?